Skip to main content
. 2015 Mar 25;6(13):11664–11675. doi: 10.18632/oncotarget.3256

Figure 5.

Figure 5

Impact of bevacizumab administration on overall survival for patients with recurrent high or low VEGFR2 expression, respectively.